^
    2d
    ANCHOR: A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=748, Active, not recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    Avastin (bevacizumab) • Focus V (anlotinib) • capecitabine • oxaliplatin
    3d
    Beromuzumab Plus Anlotinib Combined with SBRT for Patients with Hepatocellular Carcinoma Failing First-Line Targeted Therapy:A Single-Arm, Multicenter Clinical Study (ChiCTR2600117101)
    P=N/A, N=29, Not yet recruiting, Southern Medical University Southern Hospital; Southern Medical University Southern Hospital
    New trial
    |
    Focus V (anlotinib)
    3d
    A Prospective, Single-arm, Exploratory Study of Aipalolitovorilimab Combined with Anlotinib and Low-dose Radiotherapy in the Treatment of Advanced Esophageal Cancer with Prior Immunotherapy Failure. (ChiCTR2600116202)
    P=N/A, N=30, Not yet recruiting, Anhui Provincial Cancer Hospital.; Anhui Provincial Cancer Hospital
    New trial
    |
    Focus V (anlotinib)
    3d
    Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study (ChiCTR2500114484)
    P=N/A, N=34, Not yet recruiting, Qilu Hospital of Shandong University; Qilu Hospital of Shandong University
    New trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel
    3d
    A phase II clinical study on the efficacy and safety of anlotinib combined with oral etoposide capsules as first-line treatment for extensive-stage small cell lung cancer (ESSCLC) (ChiCTR2500112982)
    P=N/A, N=39, Not yet recruiting, The Pearl River Hospital of Southern Medical University; The Pearl River Hospital of Southern Medical University
    New trial
    |
    Focus V (anlotinib) • etoposide oral
    3d
    A Retrospective Study on Efficacy Evaluation of Anlotinib Combined with Temozolomide in the Treatment of Recurrent Glioma Based on Real-World Data (ChiCTR2500112913)
    P=N/A, N=144, Recruiting, The First Affiliated Hospital of Army Medical University of the Chinese People's Liberation Army; The First Affiliated Hospital of Army Medical Univer
    New trial
    |
    Focus V (anlotinib) • temozolomide
    3d
    Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus (ChiCTR2500112169)
    P=N/A, N=27, Not yet recruiting, Henan Cancer Hospital; Henan Cancer Hospital
    New trial
    |
    Focus V (anlotinib) • Tevimbra (tislelizumab-jsgr)
    3d
    Efficacy and Safety of Irinotecan Liposome Combined with Anlotinib as Second-Line Therapy for Locally Advanced or Metastatic Neuroendocrine Carcinoma Study (ChiCTR2500112112)
    P=N/A, N=55, Not yet recruiting, Jiangsu Provincial Cancer Hospital; Jiangsu Cancer Hospital
    New trial
    |
    Focus V (anlotinib)
    3d
    An Open-Label, Single-Arm, Single-Center Exploratory Clinical Study of Bemotuzumab Plus Chemotherapy With or Without Anlotinib as Neoadjuvant Therapy for Locally Advanced Cervical Cancer (ChiCTR2600116452)
    P4, N=36, Not yet recruiting, Obstetris & Gynecology Hospital of Fudan University; Obstetris & Gynecology Hospital of Fudan University
    New P4 trial
    |
    Focus V (anlotinib)
    3d
    Almonertinib plus Anlotinib for EGFR Mutant NSCLC with Progression After Third-Generation TKI Adjuvant Therapy (ChiCTR2500114326)
    P4, N=50, Recruiting, Tianjin Medical University Cancer Institute&Hospital; Tianjin Medical University Cancer Institute&Hospital
    New P4 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Focus V (anlotinib) • Ameile (aumolertinib)
    3d
    A Single-arm, Single-center Phase II Clinical Study of Sacituzumab tirumotecan Combined with Anlotinib in the Second-line Treatment of Patients with Advanced Gastric Cancer (ChiCTR2500112073)
    P4, N=33, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
    New P4 trial
    |
    Focus V (anlotinib) • Jiataile (sacituzumab tirumotecan)
    3d
    Doxorubicin alone versus eribulin with anlotinib followed by anlotinib alone as first-line therapy for metastatic or unresectable L-type sarcoma: a randomised, multicentre,open-label phase 3 trial (ChiCTR2600117706)
    P3, N=120, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New P3 trial
    |
    Focus V (anlotinib) • doxorubicin hydrochloride • Halaven (eribulin mesylate)